Literature DB >> 29251203

Combining blinatumomab with targeted therapy for BCR-ABL mutant relapsed/refractory acute lymphoblastic leukemia.

Ahmad Hanif1, Eunice S Wang2, James E Thompson2, Jeffrey I Baron2, Mark D Walsh2, Elizabeth A Griffiths2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29251203      PMCID： PMC7034710          DOI： 10.1080/10428194.2017.1411595

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  12 in total

1.  Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Oliver G Ottmann; Barbara Wassmann
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2005

2.  Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration.

Authors:  Hagop M Kantarjian; Deborah Thomas; Farhad Ravandi; Stefan Faderl; Elias Jabbour; Guillermo Garcia-Manero; Sherry Pierce; Jianquin Shan; Jorge Cortes; Susan O'Brien
Journal:  Cancer       Date:  2010-08-24       Impact factor: 6.860

3.  Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia.

Authors:  Rita Assi; Hagop Kantarjian; Nicholas J Short; Naval Daver; Koichi Takahashi; Guillermo Garcia-Manero; Courtney DiNardo; Jan Burger; Jorge Cortes; Nitin Jain; William Wierda; Salim Chamoun; Marina Konopleva; Elias Jabbour
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2017-08-18

4.  Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.

Authors:  Max S Topp; Nicola Gökbuget; Anthony S Stein; Gerhard Zugmaier; Susan O'Brien; Ralf C Bargou; Hervé Dombret; Adele K Fielding; Leonard Heffner; Richard A Larson; Svenja Neumann; Robin Foà; Mark Litzow; Josep-Maria Ribera; Alessandro Rambaldi; Gary Schiller; Monika Brüggemann; Heinz A Horst; Chris Holland; Catherine Jia; Tapan Maniar; Birgit Huber; Dirk Nagorsen; Stephen J Forman; Hagop M Kantarjian
Journal:  Lancet Oncol       Date:  2014-12-16       Impact factor: 41.316

5.  Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.

Authors:  Hagop Kantarjian; Deborah Thomas; Susan O'Brien; Jorge Cortes; Francis Giles; Sima Jeha; Carlos E Bueso-Ramos; Sherry Pierce; Jianqin Shan; Charles Koller; Miloslav Beran; Michael Keating; Emil J Freireich
Journal:  Cancer       Date:  2004-12-15       Impact factor: 6.860

6.  Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.

Authors:  Jacob M Rowe; Georgina Buck; Alan K Burnett; Raj Chopra; Peter H Wiernik; Susan M Richards; Hillard M Lazarus; Ian M Franklin; Mark R Litzow; Niculae Ciobanu; H Grant Prentice; Jill Durrant; Martin S Tallman; Anthony H Goldstone
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

7.  Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study.

Authors:  Vinod Pullarkat; Marilyn L Slovak; Kenneth J Kopecky; Stephen J Forman; Frederick R Appelbaum
Journal:  Blood       Date:  2007-12-21       Impact factor: 22.113

8.  Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial.

Authors:  Xavier Thomas; Jean-Michel Boiron; Françoise Huguet; Hervé Dombret; Ken Bradstock; Norbert Vey; Tibor Kovacsovics; André Delannoy; Nathalie Fegueux; Pierre Fenaux; Aspasia Stamatoullas; Jean-Paul Vernant; Olivier Tournilhac; Agnès Buzyn; Oumedaly Reman; Christiane Charrin; Claude Boucheix; Jean Gabert; Véronique Lhéritier; Denis Fiere
Journal:  J Clin Oncol       Date:  2004-09-07       Impact factor: 44.544

9.  Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.

Authors:  David T Teachey; Susan R Rheingold; Shannon L Maude; Gerhard Zugmaier; David M Barrett; Alix E Seif; Kim E Nichols; Erica K Suppa; Michael Kalos; Robert A Berg; Julie C Fitzgerald; Richard Aplenc; Lia Gore; Stephan A Grupp
Journal:  Blood       Date:  2013-05-15       Impact factor: 22.113

10.  Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study.

Authors:  Adele K Fielding; Susan M Richards; Rajesh Chopra; Hillard M Lazarus; Mark R Litzow; Georgina Buck; I Jill Durrant; Selina M Luger; David I Marks; Ian M Franklin; Andrew K McMillan; Martin S Tallman; Jacob M Rowe; Anthony H Goldstone
Journal:  Blood       Date:  2006-10-10       Impact factor: 22.113
View more
  2 in total

Review 1.  Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

Authors:  Iman Abou Dalle; Elias Jabbour; Nicholas J Short; Farhad Ravandi
Journal:  Curr Treat Options Oncol       Date:  2019-01-24

2.  Liposomal T cell engager and re-director for tumor cell eradication in cancer immunotherapy.

Authors:  Fang Xie; Luchen Zhang; Sanyuan Shi; Anjie Zheng; Jiaxing Di; Shanshan Jin; Xuguang Miao; Fenglan Wu; Xiaolong Chen; Yanhong Zhang; Xiaohui Wei; Yuhong Xu
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 6.440
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.